Guardant Health

Precision medicineHealthcare diagnosticsGenomic analysis

$167.47vs prev close▲+1.91(+1.15%)

$61.0052W Range$191.05

82% from low

+12.82 (+8.15%)Past 1M

Price

ARK Trade PatternPREMIUM

1M Trades

4 buys

Concentrated buys

1M net buy

+$10.8M

≈ +64K shares

Portfolio Weight

0.65%

1M +0.01%p

Holding ETFs

1 ETFs

ARKG

Buy · Weight Up

ARK net-bought the stock and the price rose, increasing its portfolio weight.

Shares +12.6% · Market value +30.9% · Weight +0.01%p

Trade Intensity

Minor adjustment

Basis: 0 sells · 4 buys in 1M

Trade Log4-day BUY streak

Date	Action	ETF	Shares	Close	Est. total
26.10.09	BUY	ARKG	7,210	$167.47	$1.2M
26.09.16	BUY	ARKG	7,738	$174.90	$1.4M
26.09.15	BUY	ARKG	9,070	$175.65	$1.6M
26.09.14	BUY	ARKG	39,558	$167.84	$6.6M
26.08.31	BUY	ARKG	56,987	$159.02	$9.1M
26.07.09	SELL	ARKG	16,105	$164.08	$2.6M
26.07.08	SELL	ARKG	6,344	$156.17	$990.7K
26.07.07	SELL	ARKG	5,602	$162.92	$912.7K
26.03.20	SELL	ARKG	9,621	$85.18	$819.5K
26.03.18	SELL	ARKG	11,757	$87.27	$1.0M
26.02.27	SELL	ARKG	27,334	$93.90	$2.6M
26.02.06	SELL	ARKG	7,097	$101.85	$722.8K
26.02.05	SELL	ARKG	7,676	$98.36	$755.0K
26.02.04	SELL	ARKG	42,317	$106.15	$4.5M
26.02.03	SELL	ARKG	4,439	$113.05	$501.8K

10.09BUY

7,210

ARKGClose$167.47Est. total$1.2M

09.16BUY

7,738

ARKGClose$174.90Est. total$1.4M

09.15BUY

9,070

ARKGClose$175.65Est. total$1.6M

09.14BUY

39,558

ARKGClose$167.84Est. total$6.6M

08.31BUY

56,987

ARKGClose$159.02Est. total$9.1M

07.09SELL

16,105

ARKGClose$164.08Est. total$2.6M

07.08SELL

6,344

ARKGClose$156.17Est. total$990.7K

07.07SELL

5,602

ARKGClose$162.92Est. total$912.7K

03.20SELL

9,621

ARKGClose$85.18Est. total$819.5K

03.18SELL

11,757

ARKGClose$87.27Est. total$1.0M

02.27SELL

27,334

ARKGClose$93.90Est. total$2.6M

02.06SELL

7,097

ARKGClose$101.85Est. total$722.8K

02.05SELL

7,676

ARKGClose$98.36Est. total$755.0K

02.04SELL

42,317

ARKGClose$106.15Est. total$4.5M

02.03SELL

4,439

ARKGClose$113.05Est. total$501.8K

1 / 6

Prices estimated from market closing prices on trade dates. Actual execution prices may differ. This is not investment advice.

Stock Timeline

Institutional Holders

2 Holding · 0 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Cathie WoodARK Invest

LIVE

604,316

Portfolio Weight

0.65%

in ETF 4.64%

Est. Value

$113M

30D Net

+$11M

Ray DalioBridgewater Associates

Increased

28,291

Portfolio Weight

0.01%

Est. Value

$3M

vs Prev Quarter

+606% (4K→28K)

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

Strong Buy

Buy

Strong Sell

Analyst Targets

avg.

$200.44

vs Current ▲ +19.7% upside

Current$167.47

Low ~ High$105.00 ~ $240.00

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

Barclays

Overweight

$220.00

+31.37%

—

Maintain

2026-10-07

Guggenheim

Buy

$200.00

+19.42%

—

Maintain

2026-10-01

UBS

Buy

$225.00

+34.35%

—

Maintain

2026-09-09

Rothschild & Co

Buy

$203.00

+21.22%

—

Upgrade

2026-09-08

BTIG

Buy

$195.00

+16.44%

—

Maintain

2026-09-02

1 / 4

Avg Target

$200.44

vs Current ▲ +19.7% upside

Strong Buy

26 analysts

Strong Buy 5Buy 20Strong Sell 1

Low $105.00

Current $167.47

High $240.00

Firm	Position	Target	Upside	Close	Action	Date
Barclays	Overweight	$220.00	+31.37%	—	Maintain	26.10.07
Guggenheim	Buy	$200.00	+19.42%	—	Maintain	26.10.01
UBS	Buy	$225.00	+34.35%	—	Maintain	26.09.09
Rothschild & Co	Buy	$203.00	+21.22%	—	Upgrade	26.09.08
BTIG	Buy	$195.00	+16.44%	—	Maintain	26.09.02

1 / 4

Price Information

Previous Close$165.56

Open$166.85

Day Range$166.03 - $170.81

52-Week Range$61.00 - $191.05

1-Year Change171.29%

Trading Volume

Volume1,519,912

Avg Volume (3mo)1,973,609

Valuation

Market Cap22.5B

Book Value$-1.67

Shares Outstanding134,196,170

Financials

Revenue (TTM)1.2B

Net Income-453,436,000

EPS$-3.50

EBITDA-430,571,008

Profitability

P/E Ratio-

P/B Ratio-100.40

Return on Equity (ROE)-

Return on Assets (ROA)-18.07%

Profit Margin-38.33%

EV/EBITDA-53.69

Beta1.58

Dividend

Dividend Rate-

Dividend Yield0.00%

Technical

RSI(14)43.02

Company Overview

Guardant Health is a precision oncology company that offers a suite of blood and tissue tests, including Guardant360 and Guardant360 CDx, to identify genetic alterations in cancer. These tests, along with data sets and software solutions like GuardantConnect, help clinicians and biopharmaceutical companies advance cancer research and therapy development. The company is a leader in liquid biopsy and comprehensive genomic profiling for cancer patients.

P/B

-100.40

Negative equity

ROE

Return on Equity

Beta

1.58

High volatility

RSI(14)

43.0

Neutral zone

AI-generated summary. Not investment advice.

Guardant Health

Analyst Consensus

Price Information

Trading Volume

Valuation

Financials

Profitability

Dividend

Technical

Related ARK stocks